A research team has investigated a new combination therapy against cancer. This therapy employs systemic administration of the tissue hormone interferon-I combined with local application of Imiquimod.

Biofrontera Inc. announced that the last patient in its Phase 3 study, ALA-BCC-CT013, of Ameluz and RhodoLED PDT for treating superficial basal cell carcinoma (sBCC) completed their one-year ...